Delay Looms For Axsome Therapeutics’ Entry Into Major Depressive Disorder Market With Lead Product
But Positive Data In Treatment-Resistant Depression
Axsome Therapeutics’ lead candidate, AXS-05, was nearing the US market for major depressive disorder, but the US company is trying to find out more about deficiencies identified by US regulators; the biotech has also reported positive Phase II results in treatment-resistant depression.
